Figure 3From: A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In VivoPPARα antagonist inhibits CLL proliferation. (A) To demonstrate CLL proliferation under the described culture conditions, CLL cells were CFSE-labeled and cocultured with activated allogeneic T cells as described in Materials and Methods. Five days after coculture, CLL cells were stained with CD19-APC and proliferation was assessed by flow cytometry. The histograms to the right show CFSE profile gated on CD19+ cells. (B) CLL cells were incubated with either PPARα antagonist NXT629 or the negative control compound NXT962 for 2 h. Subsequently, T cells were added and CLL proliferation was assessed after 5 d. The number of viable cells determined by gating on DiOC6 bright and PI negative cells with the use of Accuri software is depicted. Data are mean ± SD from three independent experiments using CLL cells from the same donor. Significant difference: *p < 0.05, **p < 0.005, unpaired Student t test. (C) CLL cells were incubated with either PPARα antagonist NXT629 or vehicle control for 2 h. Subsequently, T cells were added, and CLL proliferation was assessed after 8 d. The number of viable cells (DiOC6 bright and PI negative) was quantified by flow cytometry and normalized to the vehicle control, set as 100%. Data are mean ± SEM from 10 different CLL patient samples. (D) CLL cells were incubated as in (C) and, after 8 d, cell cycle analysis was performed using PI staining as described in Materials and Methods. Percentage of cells in G2/M and G0/1 phase was normalized to vehicle control. Data are mean ± SEM from four different CLL donors. Significant difference: *p < 0.05, **p < 0.005, unpaired Student t test.Back to article page